{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:09:21Z","timestamp":1757617761756,"version":"3.44.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1038\/s41409-025-02604-3","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T09:58:48Z","timestamp":1746439128000},"page":"1169-1174","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Attitudes and perspectives of oncologists about measurable residual disease testing in multiple myeloma: initiative for standardizing guidelines"],"prefix":"10.1038","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3795-8998","authenticated-orcid":false,"given":"Aqeeb Ur","family":"Rehman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fathima Shehnaz","family":"Ayoobkhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9609-6160","authenticated-orcid":false,"given":"Moazzam","family":"Shahzad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Kashif","family":"Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Shatnawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohaib","family":"Irfan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibgha Gull","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6914-7439","authenticated-orcid":false,"given":"Faiz","family":"Anwer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0539-4796","authenticated-orcid":false,"given":"Joseph P.","family":"McGuirk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":false,"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4336-4982","authenticated-orcid":false,"given":"Nausheen","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6603-185X","authenticated-orcid":false,"given":"Al-Ola","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8122-0563","authenticated-orcid":false,"given":"Muhammad Umair","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"key":"2604_CR1","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u201346.","journal-title":"Lancet Oncol"},{"key":"2604_CR2","doi-asserted-by":"publisher","first-page":"932852","DOI":"10.3389\/FONC.2022.932852\/BIBTEX","volume":"12","author":"V Ferla","year":"2022","unstructured":"Ferla V, Antonini E, Perini T, Farina F, Masottini S, Malato S, et al. Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy. Front Oncol. 2022;12:932852 https:\/\/doi.org\/10.3389\/FONC.2022.932852\/BIBTEX.","journal-title":"Front Oncol"},{"key":"2604_CR3","doi-asserted-by":"publisher","first-page":"e422","DOI":"10.1016\/S2352-3026(21)00130-7","volume":"8","author":"B Diamond","year":"2021","unstructured":"Diamond B, Korde N, Lesokhin AM, Smith EL, Shah U, Mailankody S, et al. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2021;8:e422\u201332. https:\/\/doi.org\/10.1016\/S2352-3026(21)00130-7.","journal-title":"Lancet Haematol"},{"key":"2604_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01113-8","volume":"14","author":"D Jevremovic","year":"2024","unstructured":"Jevremovic D, Shi M, Horna P, Otteson GE, Timm MM, Baughn LB, et al. Real-life sensitivity of flow cytometry minimal residual disease assessment for plasma cell neoplasms. Blood Cancer J. 2024;14:126.","journal-title":"Blood Cancer J"},{"key":"2604_CR5","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/BLOOD-2018-06-858613","volume":"132","author":"A Perrot","year":"2018","unstructured":"Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien ML, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018;132:2456\u201364. https:\/\/doi.org\/10.1182\/BLOOD-2018-06-858613.","journal-title":"Blood"},{"key":"2604_CR6","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1182\/BLOOD-2014-01-550020","volume":"123","author":"J Martinez-Lopez","year":"2014","unstructured":"Martinez-Lopez J, Lahuerta JJ, Pepin F, Gonz\u00e1lez M, Barrio S, Ayala R, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014;123:3073\u20139. https:\/\/doi.org\/10.1182\/BLOOD-2014-01-550020.","journal-title":"Blood"},{"key":"2604_CR7","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1038\/bmt.2016.222","volume":"51","author":"O Landgren","year":"2016","unstructured":"Landgren O, Devlin S, Boulad M, Mailankody S. Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis. Bone Marrow Transpl. 2016;51:1565\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"2604_CR8","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13045-021-01135-w","volume":"14","author":"J Martinez-Lopez","year":"2021","unstructured":"Martinez-Lopez J, Alonso R, Wong SW, Rios R, Shah N, Ruiz-Heredia Y, et al. Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma. J Hematol OncolJ Hematol Oncol. 2021;14:126.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"2604_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01156-x","volume":"14","author":"BA Derman","year":"2024","unstructured":"Derman BA, Major A, Cooperrider J, Jiang K, Ramsland A, Karrison T, et al. Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). Blood Cancer J. 2024;14:170.","journal-title":"Blood Cancer J"},{"key":"2604_CR10","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1200\/JCO.21.01935","volume":"40","author":"LJ Costa","year":"2022","unstructured":"Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al. Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. J Clin Oncol J Am Soc Clin Oncol. 2022;40:2901\u201312.","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"2604_CR11","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1182\/blood.2024024371","volume":"144","author":"O Landgren","year":"2024","unstructured":"Landgren O, Prior TJ, Masterson T, Heuck C, Bueno OF, Dash AB. EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma. Blood. 2024;144:359\u201367.","journal-title":"Blood"},{"key":"2604_CR12","unstructured":"International Myeloma Foundation. A Historic Turning Point: ODAC Unanimously Votes in Favor of MRD Testing as an Early Endpoint in Myeloma Clinical Trials to Support Accelerated Approvals of New Treatments. 2025. Available from: https:\/\/www.myeloma.org\/blog\/dr-duries\/odac-unanimously-in-favor-mrd-testing-early-endpoint-myeloma."},{"key":"2604_CR13","unstructured":"Reflection paper on the use of measurable residual disease as a clinical endpoint in multiple myeloma studies - Scientific guideline. European Medicines Agency (EMA). 2022. Available from: https:\/\/www.ema.europa.eu\/en\/reflection-paper-use-measurable-residual-disease-clinical-endpoint-multiple-myeloma-studies-scientific-guideline."},{"key":"2604_CR14","doi-asserted-by":"publisher","first-page":"e34.","DOI":"10.2196\/jmir.6.3.e34","volume":"6","author":"G Eysenbach","year":"2004","unstructured":"Eysenbach G. Improving the Quality of Web Surveys: The Checklist for Reporting Results of Internet E-Surveys (CHERRIES). J Med Internet Res,. 2004;6:e34.","journal-title":"J Med Internet Res,"},{"key":"2604_CR15","unstructured":"ClonoSEQ\u00ae Assay Technical Information. 2025. Available at: https:\/\/adaptivebiotech.showpad.com\/share\/Tyh1kHj3ORA5oD14VlSd8."},{"key":"2604_CR16","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1182\/blood-2021-144578","volume":"138","author":"K Ramasamy","year":"2021","unstructured":"Ramasamy K, Avet-Loiseau H, Blimark CH, Delforge M, Gay F, Manier S, et al. Modified Delphi Method Identifies Consensus Areas for Routine Minimal Residual Disease Testing in Multiple Myeloma. Blood. 2021;138:1631.","journal-title":"Blood"},{"key":"2604_CR17","doi-asserted-by":"publisher","first-page":"7249","DOI":"10.1182\/blood-2022-157270","volume":"140","author":"Q Wang","year":"2022","unstructured":"Wang Q, Yao L, Zhu M, Yan L, Jin S, Shang J, et al. Comparison of Next-Generation Flow Cytometry (NGF) and Next-Generation Sequencing (NGS) in the Assessment of Minimal Residual Disease in Multiple Myeloma. Blood. 2022;140:7249\u201350.","journal-title":"Blood"},{"key":"2604_CR18","doi-asserted-by":"publisher","first-page":"S546","DOI":"10.1016\/S2152-2650(24)01663-X","volume":"24","author":"LN Gordan","year":"2024","unstructured":"Gordan LN, Warner A, Heritage T, Ming A, Gupta-Werner N, Kaila S, et al. MM-318 Perspectives of Single-Center Community Hematologists\/Oncologists on Minimal Residual Disease Testing Among Patients With Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2024;24:S546. https:\/\/doi.org\/10.1016\/S2152-2650(24)01663-X.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2604_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00705-6","volume":"12","author":"BA Derman","year":"2022","unstructured":"Derman BA, Jakubowiak AJ, Thompson MA. Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma. Blood Cancer J. 2022;12:108.","journal-title":"Blood Cancer J"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02604-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02604-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02604-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T13:21:04Z","timestamp":1757164864000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02604-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2604"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02604-3","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"type":"print","value":"0268-3369"},{"type":"electronic","value":"1476-5365"}],"subject":[],"published":{"date-parts":[[2025,5,5]]},"assertion":[{"value":"19 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MUM has research funding from Iovance Biotherapeutics for an investigator-initiated trial outside of this work. NA has an advisory role in Bristol Myers Squibb and a consulting role with Kite\/Gilead. JPM has consulting and advisory roles in Bristol Myers Squibb, Kite, Novartis, AlloVir, Envision, Autolus, Nektar Therapeutics, CRISPR Therapeutics, Caribou Bio, Sana Technologies, Legend Biotech, and Cargo Therapeutics. The remaining authors declare that no other commercial or financial relationships could be construed as potential conflicts of interest. FA served as advisor and speaker for Bristol Myers Squibb, Celgene, Caribou biosciences, GI Innovation and Poseida Therapeutics; received research funding from Allogene Therapeutic, Celgene, GlaxoSmithKline, Bristol Myers Squibb, and Cariou Biosciences.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}